Meeting Eye-to-Eye: A Patient-Provider Exchange on Improving Treatment in nAMD Through Sustained Delivery (CME Webcast)
Activity Description and Purpose
The incidence of neovascular age-related macular degeneration (nAMD) is rising as a large segment of the US population ages. Despite recent advances in treatment, frequent injections and monitoring visits create a burden on patients that often leads to nonadherence, undertreatment, and suboptimal visual outcomes. In this unique educational activity, a patient with nAMD and 2 experts in retinal disease treatment discuss unmet needs in nAMD, strategies to reduce treatment burden using current therapies, and emerging strategies that harness either an implantable port or viral vectors to deliver anti–vascular endothelial growth factor therapy continuously to the vitreous. The desired results of this educational activity are for retina specialists and other ophthalmologists to use current evidence to support patient-centered treatment strategies for nAMD that minimize treatment burden while maximizing vision and quality of life outcomes.
This educational activity is intended for retina specialists and other ophthalmologists caring for patients with nAMD.
After completing this activity, participants will be better able to:
- Summarize the latest clinical trial data for approved and emerging treatments for neovascular age-related macular degeneration
- Describe recent data on the relationship between retinal fluid and visual outcomes
- Identify patients who would be good candidates for newer injection-based therapies, continuous treatment delivery, and treat-and-extend strategies for neovascular age-related macular degeneration
Arshad M. Khanani, MD, MA
Sierra Eye Associates
Clinical Associate Professor
University of Nevada, Reno School of Medicine
Dante J. Pieramici, MD
California Retina Consultants
California Retina Research Foundation
Santa Barbara, California
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Arshad M. Khanani, MD, MA, is a consultant for Adverum, Allergan, Bausch & Lomb Incorporated, Chengdu Kanghong Pharmaceutical Group Co Ltd, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., EyePoint Pharmaceuticals, Gemini Therapeutics, Genentech, Inc, Gyroscope, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Opthea, Oxurion NV, Recens Medical, Inc, and Regenxbio Inc; is on the speakers bureau for Allergan, F. Hoffman-La Roche Ltd, Genentech, Inc, and Novartis Pharmaceuticals Corporation; and is a contracted researcher for Adverum, Allergan, Chengdu Kanghong Pharmaceutical Group Co Ltd, Gemini Therapeutics, Genentech, Inc, Gyroscope, IVERIC bio, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Opthea, Oxurion NV, Recens Medical, Inc, and Regenxbio Inc.
Dante Pieramici, MD, is a consultant for Adverum, Allegro Ophthalmics, LLC, Gemini Therapeutics, Genentech, Inc, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Regenxbio Inc; and is a contracted researcher for Adverum, Aerie Pharmaceuticals, Inc, Apellis Pharmaceuticals, Chengdu Kanghong Pharmaceutical Group Co Ltd, Gemini Therapeutics, Genentech, Inc, GrayBug, Inc, Ionis Pharmaceuticals, Inc, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Santen Inc, and Stealth BioTherapeutics Inc.
Dorene has no relevant commercial relationships to disclose.
Gennady Landa, MD, has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Genentech, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Genentech, Inc.
This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 231
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation